T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.

CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...

Acloproxalap (ADX-629) is under development for the treatment of plaque psoriasis, atopic (allergic) asthma, obesity, acute alcoholic hepatitis, cytokine storm, ethanol toxicity, minimal change ...

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible combination with Hookipa, an Austrian biotech that ...

A recent study by researchers at Institute of Science Tokyo reveals the pivotal role of tristetraprolin (TTP), an RNA-binding ...

INR:3550. the daily life of the immortal king season 5 release date Breaking news! Chinese scientists reveal the mechani ...

The festive season may be a chance to rest up and recharge—but tell that to biotech dealmakers, who have been as busy as ever ...

NEW YORK, NY, USA and VIENNA, Austria I January 02, 2025 I The boards of directors (each a “Board”) of HOOKIPA Pharma Inc. (“HOOKIPA”) and Poolbeg Pharma plc ...